Lack of effect of the opioid antagonist, naltrexone, on the in situ growth of C-1300, N1E-115 and NS206 murine neuroblastoma tumor cell lines.
Attempts have been made to confirm previously reported results which demonstrated that the opioid antagonist, naltrexone, altered the in situ growth of murine neuroblastoma tumors. Adult male A/J mice were injected with tumor cells from three different cell lines of murine neuroblastoma; the spontaneously arising C-1300 line, the adrenergic clonal line N1E-115, and the cholinergic clonal line NS20Y. Naltrexone was administered daily in doses of 0.1, 0.4, or 10.0 mg/kg subcutaneously, to replicate the reported experimental design. In contrast to previous studies, we were unable to demonstrate any effect of naltrexone on in situ growth or other characteristics of tumors produced by the C-1300, N1E-115 or NS20Y murine neuroblastoma cell lines. Ligand binding studies have demonstrated the presence of high levels of opiate binding sites on membranes prepared from the NS20Y clonal cell line and low levels on the membranes of the C1300 tumor line.
Horn
P T
PT
Department of Pediatrics, University of Minnesota Health Sciences Center, Minneapolis 55455.
Mirkin
B L
BL
D000818:Animals; D001835:Body Weight; D016009:Chi-Square Distribution; D004723:Endorphins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D009271:Naltrexone / Q000378:metabolism / Q000494:pharmacology*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental; D009447:Neuroblastoma / Q000188:drug therapy* / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D014407:Tumor Cells, Cultured
D004723:Endorphins; D011957:Receptors, Opioid; D009271:Naltrexone